Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Equity Ratio: 2020-2023

Historic Equity Ratio for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to 0.46.

  • Candel Therapeutics' Equity Ratio fell 25.00% to 0.46 in Q3 2023 from the same period last year, while for Sep 2023 it was 0.46, marking a year-over-year decrease of 25.00%. This contributed to the annual value of 0.61 for FY2022, which is 14.58% down from last year.
  • Per Candel Therapeutics' latest filing, its Equity Ratio stood at 0.46 for Q3 2023, which was down 12.26% from 0.52 recorded in Q2 2023.
  • Candel Therapeutics' 5-year Equity Ratio high stood at 0.72 for Q4 2021, and its period low was -1.40 during Q2 2021.
  • Moreover, its 3-year median value for Equity Ratio was 0.61 (2022), whereas its average is 0.40.
  • As far as peak fluctuations go, Candel Therapeutics' Equity Ratio spiked by 216.82% in 2021, and later dropped by 25.00% in 2023.
  • Candel Therapeutics' Equity Ratio (Quarterly) stood at -0.62 in 2020, then spiked by 216.82% to 0.72 in 2021, then fell by 14.58% to 0.61 in 2022, then decreased by 25.00% to 0.46 in 2023.
  • Its Equity Ratio stands at 0.46 for Q3 2023, versus 0.52 for Q2 2023 and 0.59 for Q1 2023.